SOTA EMPAG
Disease area: Diabetes
Funder: Sanofi Aventis
A 26-week randomized, double-blind, controlled, parallel-group, multicenter study to evaluate the efficacy and safety of Sotagliflozin compared to Empagliflozin, and placebo in patients with type 2 diabetes who have inadequate glycemic control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) with or without Metformin
PATRO
Disease area: Growth hormone deficiancy
Funder: SANDOZ
Post-Marketing Surveillance to monitor the long-term safety and efficacy of Omnitrope in the treatment of children and adults. PATROa (adults) PATROc (children).
Trialnet
Disease area: Type 1 diabetes
Funder: National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Juvenile Diabetes research Foundation and the American Diabetes Association
Natural History Study of the Development of Type 1 Diabetes. Phase 1,2 and 3.
Rewind
Disease area: Type 2 diabetes
Funder: Eli Lilly and Company
The Effect of LY2189265 on Major Cardiovascular Events in Patients with Type 2 Diabetes: Reducing Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)
Reversing PCOS
Disease area: Polycystic ovary syndrome
Funder: Hull and East Yorkshire Hospitals NHS Trust, and partially supported by Cambridge Weight company
A randomised controlled trial to investigate the effect of very low calorie diet (VLCD) versus an energy deficit approach weight loss diet, over 8 weeks, in obese women with polycystic ovarian syndrome (PCOS).
Clear Harmony
Disease area: Hypercholesterolemia
Funder: Esperion Therapeutics
A multicentre open – lable extension (OLE) study to assess the long term safety and efficacy of Bempedoic Acid (ETC-1002) 180 MG
LIBERATES
Disease area: Type 2 diabetes
Funder: National institute for Health research for patient benefit (RfPB)
Improving glucose control in patients with Diabetes following myocardial infarction: the role of a novel glycaemia monitoring strategy.
Transition in Type 1 Diabetes
Disease area: Type 1 diabetes
Funder: Hull CCG
Determining the perspectives of service users and carers on the transition from adolescent to adult type 1 diabetes services within Hull and East Yorkshire, and how access/support can be improved.
Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency. Front Endocrinol (Lausanne)2018; 9:56
Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Keevil B, Atkin SL. Salivary and serum androgens with anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Sci Rep2018; 8:3795
Konya J, Al Qaissi A, Sathyapalan T, Ajjan R, Madden L, Naseem KM, Garrett AT, Kilpatrick E, Atkin SL. The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes - A Cross-over Study. Front Endocrinol (Lausanne)2018; 9:26
Chattopadhyay S, George A, John J, Sathyapalan T. Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes. Acta Diabetol2018; 55:449-458
Papageorgiou M, Wells L, Williams C, White K, De Santis B, Liu Y, Debegnach F, Miano B, Moretti G, Greetham S, Brera C, Atkin SL, Hardie LJ, Sathyapalan T. Assessment of Urinary Deoxynivalenol Biomarkers in UK Children and Adolescents. Toxins (Basel)2018; 10
Sathyapalan T, Javed Z, Rigby AS, Kilpatrick ES, Atkin SL. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. J Endocr Soc2017; 1:423-430
Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Atkin SL. Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf)2018; 88:258-262
Sathyapalan T, Aye M, Rigby AS, Fraser WD, Kilpatrick ES, Atkin SL. Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - a randomised controlled study. Sci Rep2017; 7:15366
O'Doherty AF, Jones HS, Sathyapalan T, Ingle L, Carroll S. The Effects of Acute Interval Exercise and Strawberry Intake on Postprandial Lipemia. Med Sci Sports Exerc2017; 49:2315-2323
Sathyapalan T, Coady AM, Kilpatrick ES, Atkin SL. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocr Connect2017; 6:811-816
Gonzalez S, Windram JD, Sathyapalan T, Javed Z, Clark AL, Atkin SL. Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. J Int Med Res2017; 45:1708-1719
Sathyapalan T, Dickerson EH, Maguiness SM, Robinson J, Dakroury YHZ, Atkin SL. Androstenedione and testosterone levels correlate with in vitro fertilization rates in insulin-resistant women. BMJ Open Diabetes Res Care2017; 5:e000387
Dawson AJ, Kilpatrick ES, Coady AM, Elshewehy AMM, Dakroury Y, Ahmed L, Atkin SL, Sathyapalan T. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord2017; 17:41
Wells L, Hardie L, Williams C, White K, Liu Y, De Santis B, Debegnach F, Moretti G, Greetham S, Brera C, Papageorgiou M, Thatcher NJ, Rigby A, Atkin SL, Sathyapalan T. Deoxynivalenol Biomarkers in the Urine of UK Vegetarians. Toxins (Basel)2017; 9
Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Adaway J, Keevil B, Atkin SL. Salivary testosterone measurement in women with and without polycystic ovary syndrome. Sci Rep2017; 7:3589
Cho LW, Sathyapalan T, Kilpatrick ES, Keevil BG, Miller AG, Coady AM, Ahmed L, Atkin SL. Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. BMC Endocr Disord2017; 17:26
Sathyapalan T, Rigby AS, Bhasin S, Thatcher NJ, Kilpatrick ES, Atkin SL. Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism: A Randomized Controlled Study. J Clin Endocrinol Metab2017; 102:425-433
Mr Abayomi Sanusi - Multimorbidities in patients with diabetes and metabolic disorders (PhD 2019-2022) (Principal Supervisor: Professor Thozhukat Sathyapalan)
Katie Bird - Evaluation of pharmacology prescribing assessment for undergraduate medical students (Principal Supervisor: Professor Thozhukat Sathyapalan)
Alexandra Macnamara - Evaluation of pharmacology teaching for undergraudate medical students (Principal Supervisor: Professor Thozhukat Sathyapalan)
Dr Mo Aye – Hull Hip fracture Intervention and Prevention Programme (HHIPP) (PhD 2015-18) OSPREY – osteoporosis research charity. (Principal Supervisor: Professor Thozhukat Sathyapalan)
Youssra HZ Dakroury - Vitamin D effects in Qatari population (MSc 2018-19), Weill Cornell at Qatar (Principal Supervisor: Professor Thozhukat Sathyapalan)
Mr REJ England - Parameters for parathyroid surgery in hyperparathyroidism (MD - 2018)
Saeed Alqarni - Endoparticle profile in patients with type 2 diabetes (PhD 2015-18) (Co-supervisor: Professor Thozhukat Sathyapalan)
The use of digital technology in patients with type 1 diabetes attending transition clinic - Hull CCG, transformation funding - £20,000. 2018
Contigency funding for research nurse - Yorkshire and Humber CRN 2017-18 £15,307
Contingency funding from CRN Yorkshire and Humber (2016-17) - £30,894 (to HEY NHS Trust)
Measurement of stress hormones in hair - HEIF funding - (2016-17) £22,500
Hull Hip Fracture Intervention and Prevention Study (HHIPS). (2017-19) – Osteoporosis Research in East Yorkshire (OSPREY), UK. - Principal Investigator. £50,000
Service users’ perspectives in accessing type 2 services within Hull. (2016-17) Yorkshire and Humber Commissioning Support, UK – Principal Investigator. £22,864
Service users’ perspectives in accessing type 2 services within East Riding of Yorkshire. (2016-17) Yorkshire and Humber Commissioning Support, UK – Principal Investigator. £9,919.00